| Name | Creo Medical Group |
|---|---|
| Epic | CREO |
| Isin | GB00BZ1BLL44 |
| Index | MID300 |
| Industry | Medical Equipment and Services |
| Latest share price | 31.25p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £113.06 | Debt ratio | n/a |
| Shares in issue | 361.48 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -85.85 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -14.48 | 52-week high / low | 28.25p / 48.10p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Creo Medical Group |
|---|---|
| Address | Creo House, Unit 2 Beaufort Park, Beaufort Park Way, Chepstow, Wales, United Kingdom, NP16 5UH |
| Telephone | +44 (0) 1291 606005 |
| Website | http://creomedical.com/ |
| Director | Position |
|---|---|
| Mr Craig Jonathan Gulliford | CEO |
| Mr Richard John Rees | CFO |
| Mr David Gerard Woods | Executive Director |
| Mr Christopher Paul Hancock | Chief Technology Officer |
| Mr Charles Spicer | Non-Executive Chairman |
| Mrs Ivonne Cantu | Independent Non-Executive Director |
| Mr John Bradshaw | Independent Non-Executive Director |
| Assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
| Intangible asssets and goodwill | 27.64 | 27.25 | 28.53 |
| Investments and other non-current assets | 2.12 | 1.73 | 0.5 |
| Total non-current assets | 41.65 | 39.44 | 32.99 |
| Inventory / work in progress | 9.32 | 8.5 | 6.81 |
| Trade and other receivables | 11.27 | 9.13 | 5.63 |
| Cash and equivalents | 13.1 | 43.53 | 45.09 |
| Other current assets and asset held for resale | n/a | n/a | 2.97 |
| Total of all assets | 75.34 | 100.61 | 93.5 |
| Liabilities £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 17.48 | 19.74 | 21.84 |
| Long term liabilities | 8.45 | 7.55 | 8.86 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 25.93 | 27.29 | 30.7 |
| Net assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 49.4 | 73.32 | 62.81 |
| Equity £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 0.18 | 0.18 | 0.16 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -122.7 | -95.76 | -71.16 |
| Share premium account | 149.52 | 149.45 | 115.26 |
| Total equity | 49.4 | 73.32 | 62.81 |
| Income £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -30.76 | -29.91 | -23.48 |
| Pre-tax profit | -30.98 | -30.34 | -23.46 |